MedPage Today:  “Barely one-quarter of patients with cancer obtained protection against COVID-19 after one dose of the Pfizer/BioNTech vaccine, a prospective study showed.

The data found a “strikingly low” 28% immune efficacy rate in patients with cancer, including 13% in patients with blood cancers. In contrast, first-dose seroconversion occurred in 97% of a healthy control group, Adrian Hayday, PhD, of King’s College London, and co-authors concluded in a report posted to the preprint server medRxiv.

A second dose at day 21, however, brought adequate immunity to nearly all the cancer patients, they said.”

Read  more Read more here

Cancer Patients Respond Poorly to First COVID mRNA Vax Dose

— Results emphasize need to avoid long delay between doses



Submit a Comment